Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Clover Biopharmaceuticals Ltd. ( (HK:2197) ) is now available.
Clover Biopharmaceuticals Ltd. announced that its board of directors will convene on March 24, 2025, to review and approve the company’s annual financial results for 2024 and consider the declaration of a final dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder confidence.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. operates in the biotechnology industry, focusing on the development of innovative vaccines and biologic therapeutics. The company is known for its commitment to addressing global health challenges and enhancing healthcare outcomes.
YTD Price Performance: 35.42%
Average Trading Volume: 1,509,092
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$421.5M
See more data about 2197 stock on TipRanks’ Stock Analysis page.